论文部分内容阅读
目的观察奈达铂腔内灌注治疗恶性浆膜腔积液的疗效及安全性。方法恶性浆膜腔积液患者50例,在B超引导下穿刺置管闭式引流,充分引流积液后给予腔内注入奈达铂每次50mg,每周1次,3周为1个周期,共2个周期。每个周期超声测量积液量,评价疗效及安全性。结果治疗2个周期,完全缓解10例,部分缓解16例,疾病稳定11例,疾病进展13例,总有效率为52.0%。浆膜腔内灌注治疗后常见的不良反应主要有发热、骨髓抑制、恶心、呕吐和局部疼痛不适等,对症处理后上述症状均有改善。结论奈达铂腔内灌注治疗恶性浆膜腔积液疗效肯定,且不良反应可以耐受。
Objective To observe the efficacy and safety of nedaplatin intraluminal perfusion in the treatment of malignant serous effusions. Methods Fifty patients with malignant serosal effusion were treated with closed catheterization under the guidance of B-ultrasonography. After sufficient drainage of fluid, 50 mg of nedaplatin was injected into the cavity once a week for 3 weeks , A total of 2 cycles. The volume of effusion was measured by ultrasound every cycle to evaluate the efficacy and safety. Results The treatment of two cycles, complete remission in 10 cases, partial remission in 16 cases, stable disease in 11 cases, disease progression in 13 cases, the total effective rate was 52.0%. Serous cavity infusion therapy common adverse reactions are fever, myelosuppression, nausea, vomiting and local pain discomfort, symptomatic treatment of the above symptoms have improved. Conclusion Nedaplatin intraluminal perfusion treatment of malignant serous effusion positive effect, and adverse reactions can be tolerated.